Pathophysiological and Therapeutic Aspects of Urogenital Cancers
A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cellular Pathology".
Deadline for manuscript submissions: closed (31 October 2022) | Viewed by 543
Special Issue Editors
2. Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan
3. School of Medicine, Chung Shan Medical University, Taichung, Taiwan
Interests: oncology; urogenital cancer; urology; prostate cancer; bladder cancer; renal tumors; cancer biology; tumor microenvironment; prognostic biomarkers; urolithiasis
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Urogenital cancers include tumours of the kidney and bladder, and, in men, of the prostate and testicle pose considerable challenges to the urologist. Though biologically characterized and sub-classified kidney cancer was identified, identifying molecular targets to effectively treat patients with kidney cancer is remains a challenge. For bladder cancer, alternative treatment to overcome recurrent tumour with resistance of chemo drug under intravesical instillation should be evaluated. In prostate cancer, as germline testing and molecular/biomarker analysis are recommended in daily practice, the changes in molecular and signalling pathways along the therapeutic strategy would be the key issue for clinical practice. As testicular cancer patients have remarkably high cure rates, most patients are diagnosed at a young age, leaving decades for the development of treatment-related complications. This special edition is intended to provide an overview of pathophysiological and therapeutic aspects of urogenital cancers and thus open up new insights for physicians. With this letter I cordially invite all colleagues from the fields of urogenital cancers to contribute their data and experiences to the readership of ´Cancers´.
Dr. Wen-Wei Sung
Dr. Wen-Wei Chang
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- kidney cancer
- bladder cancer
- prostate cancer
- testicular cancer
- upper tract urothelial carcinoma
- retroperitoneal tumor
